$Hims & Hers Health Inc.(HIMS)$ HIMS tanked 30% after Novo Nordisk ditched the Wegovy tie-up, but imo that overreaction is wild—first-quarter sales crushed estimates, retail’s piling in on any dip, and with $49.5 M net income & tight margins, this telemed play’s got legs

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment1

  • Top
  • Latest
  • limzihao03
    ·06-25
    no niche, management ditching shares, overvalued. definitely wouldnt hold long
    Reply
    Report